Review



psb 603  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress psb 603
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb 603, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB-603/pmc13121447-44-12-14
    Average 94 stars, based on 4 article reviews
    psb 603 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies"

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies

    Journal: Scientific Reports

    doi: 10.1038/s41598-026-43642-1

    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C ), PSB-603 for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Figure Legend Snippet: Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C ), PSB-603 for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.

    Techniques Used: Activation Assay, CCK-8 Assay

    Related Articles

    Activation Assay:

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies.
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    CCK-8 Assay:

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies.
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Labeling:

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies.
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Derivative Assay:

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies.
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Expressing:

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies.
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Injection:

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies.
    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.



    Similar Products

    psb 603  (MedChemExpress)
    94
    MedChemExpress psb 603
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb 603, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB-603/pmc13121447-44-12-14
    Average 94 stars, based on 1 article reviews
    psb 603 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    psb603  (Tocris)
    94
    Tocris psb603
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb603, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB+603/pm41506868-225-3-11
    Average 94 stars, based on 1 article reviews
    psb603 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    psb 603  (Tocris)
    94
    Tocris psb 603
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb 603, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB+603/pmc12910660-180-3-11
    Average 94 stars, based on 1 article reviews
    psb 603 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    a2br antagonist 8  (Tocris)
    94
    Tocris a2br antagonist 8
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    A2br Antagonist 8, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB+603/pm41115591-162-29-34
    Average 94 stars, based on 1 article reviews
    a2br antagonist 8 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    psb-603  (TargetMol)
    93
    TargetMol psb-603
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb 603, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB-603/targetmol___t23203
    Average 93 stars, based on 1 article reviews
    psb-603 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    psb 603  (TargetMol)
    93
    TargetMol psb 603
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb 603, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB+603/pm41033606-41-10-50
    Average 93 stars, based on 1 article reviews
    psb 603 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    chlorophenzyl piperazide 1 sulfonyl phenyl 1 propylxanthine  (Tocris)
    94
    Tocris chlorophenzyl piperazide 1 sulfonyl phenyl 1 propylxanthine
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Chlorophenzyl Piperazide 1 Sulfonyl Phenyl 1 Propylxanthine, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB+603/pm32271569__jm0c00235_si_001-5-37-40
    Average 94 stars, based on 1 article reviews
    chlorophenzyl piperazide 1 sulfonyl phenyl 1 propylxanthine - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    psb  (Tocris)
    94
    Tocris psb
    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
    Psb, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psb+603/PSB+603/pm40583388-237-14-18
    Average 94 stars, based on 1 article reviews
    psb - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C ), PSB-603 for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.

    Journal: Scientific Reports

    Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies

    doi: 10.1038/s41598-026-43642-1

    Figure Lengend Snippet: Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C ), PSB-603 for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.

    Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

    Techniques: Activation Assay, CCK-8 Assay